• +1-646-491-9876
    • +91-20-67278686

    Search

    Hospital Acquired Pneumonia (HAP) - Pipeline Review, H1 2017

    Hospital Acquired Pneumonia (HAP) - Pipeline Review, H1 2017

    • Report Code ID: RW0001689412
    • Category Healthcare
    • No. of Pages 153
    • Publication Month Feb-17
    • Publisher Name Global Markets Direct
    Report Summary

    Publisher's latest Pharmaceutical and Healthcare disease pipeline guide Hospital Acquired Pneumonia (HAP) - Pipeline Review, H1 2017, provides an overview of the Hospital Acquired Pneumonia (HAP) (Infectious Disease) pipeline landscape.

    Hospital Acquired Pneumonia (HAP) is defined as pneumonia acquired during hospital stay. Symptoms include cough, fever, shaking chills, confusion, headache and loss of appetite. Risk factors include chronic lung disease, cigarette smoking, dementia, stroke, brain injury, heart disease, liver cirrhosis and diabetes mellitus. Treatment includes antibiotics and healthy lifestyle.

    Report Highlights

    Publisher's Pharmaceutical and Healthcare latest pipeline guide Hospital Acquired Pneumonia (HAP) - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Hospital Acquired Pneumonia (HAP) (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

    The Hospital Acquired Pneumonia (HAP) (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Hospital Acquired Pneumonia (HAP) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 8, 8, 7, 12, 1 and 1 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.

    Hospital Acquired Pneumonia (HAP) (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Publisher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

    Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

    Report Scope

    - The pipeline guide provides a snapshot of the global therapeutic landscape of Hospital Acquired Pneumonia (HAP) (Infectious Disease).
    - The pipeline guide reviews pipeline therapeutics for Hospital Acquired Pneumonia (HAP) (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
    - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
    - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
    - The pipeline guide reviews key companies involved in Hospital Acquired Pneumonia (HAP) (Infectious Disease) therapeutics and enlists all their major and minor projects.
    - The pipeline guide evaluates Hospital Acquired Pneumonia (HAP) (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
    - The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
    - The pipeline guide reviews latest news related to pipeline therapeutics for Hospital Acquired Pneumonia (HAP) (Infectious Disease)

    Reasons to buy

    - Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
    - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
    - Find and recognize significant and varied types of therapeutics under development for Hospital Acquired Pneumonia (HAP) (Infectious Disease).
    - Classify potential new clients or partners in the target demographic.
    - Develop tactical initiatives by understanding the focus areas of leading companies.
    - Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
    - Formulate corrective measures for pipeline projects by understanding Hospital Acquired Pneumonia (HAP) (Infectious Disease) pipeline depth and focus of Indication therapeutics.
    - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
    - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
    Table of Contents
    List of Tables
    List of Figures
    Introduction
    Publisher Report Coverage
    Hospital Acquired Pneumonia (HAP) - Overview
    Hospital Acquired Pneumonia (HAP) - Therapeutics Development
    Pipeline Overview
    Pipeline by Companies
    Pipeline by Universities/Institutes
    Products under Development by Companies
    Products under Development by Universities/Institutes
    Hospital Acquired Pneumonia (HAP) - Therapeutics Assessment
    Assessment by Target
    Assessment by Mechanism of Action
    Assessment by Route of Administration
    Assessment by Molecule Type
    Hospital Acquired Pneumonia (HAP) - Companies Involved in Therapeutics Development
    Achaogen Inc
    Adenium Biotech ApS
    Aridis Pharmaceuticals LLC
    AstraZeneca Plc
    Bayer AG
    Cardeas Pharma Corp
    Destiny Pharma Ltd
    Dong-A Socio Holdings Co Ltd
    Lakewood-Amedex Inc
    MedImmune LLC
    Meiji Seika Pharma Co Ltd
    Melinta Therapeutics Inc
    Merck & Co Inc
    Motif Bio Plc
    Nabriva Therapeutics AG
    Polyphor Ltd
    Sealife PHARMA GMBH
    Shionogi & Co Ltd
    Tetraphase Pharmaceuticals Inc
    TGV-Inhalonix Inc
    The Medicines Company
    Theravance Biopharma Inc
    Wockhardt Ltd
    Zavante Therapeutics Inc
    Hospital Acquired Pneumonia (HAP) - Drug Profiles
    (amikacin sulfate + fosfomycin) - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    (avibactam + ceftazidime) - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    (avibactam sodium + aztreonam lysine) - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    (ceftolozane sulfate + tazobactam sodium) - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    (cilastatin sodium + imipenem + relebactam) - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    (meropenem+ vaborbactam) - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    (Pseudomonas + ventilator associated pneumonia) vaccine - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    AA-139 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Aerucin - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    alalevonadifloxacin - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    amikacin sulfate - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    arbekacin - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    cefepime + zidebactam - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    cefiderocol - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    delafloxacin - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    EBX-004 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    eravacycline - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    exeporfinium chloride - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    fosfomycin tromethamine - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    iclaprim mesylate - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    lefamulin acetate - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Levonadifloxacin - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    MEDI-3902 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Mul-1867 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Nu-2 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Nu-3 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Panaecin - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    panobacumab - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    plazomicin sulfate - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    POL-7001 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Qn-2251 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    SLP-0905 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    sodium hypochlorite - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    suvratoxumab - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    tedizolid phosphate - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    telavancin hydrochloride - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    tosatoxumab - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Viritron VDX - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Hospital Acquired Pneumonia (HAP) - Dormant Projects
    Hospital Acquired Pneumonia (HAP) - Discontinued Products
    Hospital Acquired Pneumonia (HAP) - Product Development Milestones
    Featured News & Press Releases
    Oct 31, 2016: New Data On Iclaprim Released At Idweek 2016; Iclaprim Shown To Be Highly Potent Against SSSI And HABP Clinical Isolates
    Oct 31, 2016: Theravance Biopharma Presents Interim Data from Ongoing Telavancin Observational Use Registry (TOUR) at IDWeek 2016
    Jul 21, 2016: AstraZeneca's antibiotic Zavicefta met primary endpoints in Phase III trial for treatment of hospital-acquired pneumonia
    Jun 28, 2016: New antibiotic Zavicefta approved in the European Union for patients with serious bacterial infections
    Jun 28, 2016: New antibiotic Zavicefta approved in the European Union for patients with serious bacterial infections
    Jun 20, 2016: Results of Phase 2 Study of Merck's Investigational Beta-Lactamase Inhibitor Relebactam in Combination with Imipenem/Cilastatin Presented at ASM Microbe
    May 16, 2016: New Data Analyses From Phase 3 ATTAIN Trials Support VIBATIV(R) (Telavancin) as a Treatment for Staphylococcus Aureus HABP/VABP, Including Cases Caused by MRSA
    May 16, 2016: New Data Analyses From Phase 3 ATTAIN Trials Support VIBATIV(R) (Telavancin) as a Treatment for Staphylococcus Aureus HABP/VABP, Including Cases Caused by MRSA
    May 11, 2016: Theravance Biopharma to Present New Data Analyses From Phase 3 ATTAIN Trials of VIBATIV (telavancin) in Treatment of HABP/VABP at American Thoracic Society 2016 International Conference
    May 11, 2016: Theravance Biopharma to Present New Data Analyses From Phase 3 ATTAIN Trials of VIBATIV (telavancin) in Treatment of HABP/VABP at American Thoracic Society 2016 International Conference
    Apr 11, 2016: VIBATIV (Telavancin) Shows Greater In Vitro Potency Against Difficult-to-Treat Pathogens Causing Hospital-Acquired Bacterial Pneumonia, Including MRSA, Compared to Alternative Antibiotic Treatments
    Apr 04, 2016: Theravance Biopharma to Present New Data Demonstrating Potent in vitro Activity for VIBATIV (telavancin) Against Difficult-to-Treat Infections, Including MRSA, at 2016 ECCMID Conference
    Feb 26, 2016: Pendopharm Launches Vibativ In Canada
    Feb 26, 2016: Pendopharm Launches Vibativ In Canada
    Feb 24, 2016: Aridis Pharmaceuticals Expands Patent Portfolio for Several Fully Human Monoclonal Antibodies Against Infectious Disease Targets
    Appendix
    Methodology
    Coverage
    Secondary Research
    Primary Research
    Expert Panel Validation
    Contact Us
    Disclaimer

    List of Tables

    Number of Products under Development for Hospital Acquired Pneumonia (HAP), H1 2017
    Number of Products under Development by Companies, H1 2017
    Number of Products under Development by Companies, H1 2017 (Contd..1), H1 2017
    Number of Products under Development by Universities/Institutes, H1 2017
    Products under Development by Companies, H1 2017
    Products under Development by Companies, H1 2017 (Contd..1), H1 2017
    Products under Development by Companies, H1 2017 (Contd..2), H1 2017
    Products under Development by Companies, H1 2017 (Contd..3), H1 2017
    Products under Development by Universities/Institutes, H1 2017
    Number of Products by Stage and Target, H1 2017
    Number of Products by Stage and Mechanism of Action, H1 2017
    Number of Products by Stage and Route of Administration, H1 2017
    Number of Products by Stage and Molecule Type, H1 2017
    Hospital Acquired Pneumonia (HAP) - Pipeline by Achaogen Inc, H1 2017
    Hospital Acquired Pneumonia (HAP) - Pipeline by Adenium Biotech ApS, H1 2017
    Hospital Acquired Pneumonia (HAP) - Pipeline by Aridis Pharmaceuticals LLC, H1 2017
    Hospital Acquired Pneumonia (HAP) - Pipeline by AstraZeneca Plc, H1 2017
    Hospital Acquired Pneumonia (HAP) - Pipeline by Bayer AG, H1 2017
    Hospital Acquired Pneumonia (HAP) - Pipeline by Cardeas Pharma Corp, H1 2017
    Hospital Acquired Pneumonia (HAP) - Pipeline by Destiny Pharma Ltd, H1 2017
    Hospital Acquired Pneumonia (HAP) - Pipeline by Dong-A Socio Holdings Co Ltd, H1 2017
    Hospital Acquired Pneumonia (HAP) - Pipeline by Lakewood-Amedex Inc, H1 2017
    Hospital Acquired Pneumonia (HAP) - Pipeline by MedImmune LLC, H1 2017
    Hospital Acquired Pneumonia (HAP) - Pipeline by Meiji Seika Pharma Co Ltd, H1 2017
    Hospital Acquired Pneumonia (HAP) - Pipeline by Melinta Therapeutics Inc, H1 2017
    Hospital Acquired Pneumonia (HAP) - Pipeline by Merck & Co Inc, H1 2017
    Hospital Acquired Pneumonia (HAP) - Pipeline by Motif Bio Plc, H1 2017
    Hospital Acquired Pneumonia (HAP) - Pipeline by Nabriva Therapeutics AG, H1 2017
    Hospital Acquired Pneumonia (HAP) - Pipeline by Polyphor Ltd, H1 2017
    Hospital Acquired Pneumonia (HAP) - Pipeline by Sealife PHARMA GMBH, H1 2017
    Hospital Acquired Pneumonia (HAP) - Pipeline by Shionogi & Co Ltd, H1 2017
    Hospital Acquired Pneumonia (HAP) - Pipeline by Tetraphase Pharmaceuticals Inc, H1 2017
    Hospital Acquired Pneumonia (HAP) - Pipeline by TGV-Inhalonix Inc, H1 2017
    Hospital Acquired Pneumonia (HAP) - Pipeline by The Medicines Company, H1 2017
    Hospital Acquired Pneumonia (HAP) - Pipeline by Theravance Biopharma Inc, H1 2017
    Hospital Acquired Pneumonia (HAP) - Pipeline by Wockhardt Ltd, H1 2017
    Hospital Acquired Pneumonia (HAP) - Pipeline by Zavante Therapeutics Inc, H1 2017
    Hospital Acquired Pneumonia (HAP) - Dormant Projects, H1 2017
    Hospital Acquired Pneumonia (HAP) - Discontinued Products, H1 2017

    List of Figures

    Number of Products under Development for Hospital Acquired Pneumonia (HAP), H1 2017
    Number of Products under Development by Companies, H1 2017
    Number of Products by Top 10 Targets, H1 2017
    Number of Products by Stage and Top 10 Targets, H1 2017
    Number of Products by Top 10 Mechanism of Actions, H1 2017
    Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017
    Number of Products by Routes of Administration, H1 2017
    Number of Products by Stage and Routes of Administration, H1 2017
    Number of Products by Molecule Types, H1 2017
    Number of Products by Stage and Molecule Types, H1 2017
    Achaogen Inc
    Adenium Biotech ApS
    Aridis Pharmaceuticals LLC
    AstraZeneca Plc
    Bayer AG
    Cardeas Pharma Corp
    Destiny Pharma Ltd
    Dong-A Socio Holdings Co Ltd
    Lakewood-Amedex Inc
    MedImmune LLC
    Meiji Seika Pharma Co Ltd
    Melinta Therapeutics Inc
    Merck & Co Inc
    Motif Bio Plc
    Nabriva Therapeutics AG
    Polyphor Ltd
    Sealife PHARMA GMBH
    Shionogi & Co Ltd
    Tetraphase Pharmaceuticals Inc
    TGV-Inhalonix Inc
    The Medicines Company
    Theravance Biopharma Inc
    Wockhardt Ltd
    Zavante Therapeutics Inc

    Request for Sample

    Report Url http://www.reportsweb.com//hospital-acquired-pneumonia-hap-pipeline-review-h1-2017&type=sample
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire before Buying

    Report Url http://www.reportsweb.com//hospital-acquired-pneumonia-hap-pipeline-review-h1-2017&type=buying
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire for Discount

    Report Url http://www.reportsweb.com//hospital-acquired-pneumonia-hap-pipeline-review-h1-2017&type=discount
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments